Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 6/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593027 | 0.93 | TSHR (0.51) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL10211108 | 0.93 | TSHR (0.52) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL10209540 | 0.89 | TSHR (0.50) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL13593908 | 0.88 | TSHR (0.48) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL13161900 | 0.87 | TSHR (0.49) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL13161344 | 0.86 | PARP1 (0.53) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL13161327 | 0.86 | TSHR (0.51) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL10209799 | 0.86 | TSHR (0.51) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL14074795 | 0.85 | TSHR (0.46) | TSHRMAOAPARP1MMP8MMP13 | |
| SCHEMBL14470130 | 0.85 | TSHR (0.50) | TSHRMAOAPARP1MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | TSHR 4659/4885MAOA 337/4885PARP1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.